MB
MRNA icon

MidFirst Bank’s Moderna MRNA Stock Holding History

MidFirst Bank’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350 Hold
5
– – ﹤0.01% 870
2026
Q1 		$254 Buy
+5
New +$233 ﹤0.01% 866

Other funds holding MRNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MidFirst Bank's MRNA Position: Q2 2026 in Review

MidFirst Bank held its Moderna (MRNA) position steady in Q2 2026 at 5 shares worth $350. The position accounts for ﹤0.01% of the portfolio, ranked #870.

MidFirst Bank first reported a position in MRNA in Q1 2026 and has held it in 2 quarters since. 614 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • MidFirst Bank held 5 shares of Moderna worth $350 as of Q2 2026.
  • MidFirst Bank left its Moderna share count unchanged in Q2 2026.
  • Moderna made up ﹤0.01% of MidFirst Bank's portfolio in Q2 2026, its #870 holding.
  • MidFirst Bank first reported a position in Moderna in Q1 2026 and has held it in 2 quarters since.
  • 614 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on MidFirst Bank's 13F filing for Q2 2026, filed 7 Aug 2026.